Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Biotech
ESMO: BMS believes ADC data allow it to 'stay ahead' of rivals
Bristol Myers Squibb touted a 55% overall response rate from one cohort of an early-stage study of its EGFRxHER3 antibody-drug conjugate.
James Waldron
Oct 17, 2025 10:30am
BMS inks $1.5B deal to pull Orbital into its sphere of influence
Oct 10, 2025 8:45am
Ono's BMS-partnered IO drug passes phase 2 gastric cancer test
Oct 9, 2025 10:10am
BMS, Takeda join peers in push to improve AI by pooling data
Oct 1, 2025 10:34am
BMS reports phase 3 win in multiple myeloma
Sep 23, 2025 8:20am
CatalYm C-suite shake-up sees 4 new faces, 3 departures
Sep 15, 2025 10:53am
